Tissue transglutaminase expression promotes cell attachment, invasion and survival in breast cancer cells
- PMID: 17043648
- DOI: 10.1038/sj.onc.1210035
Tissue transglutaminase expression promotes cell attachment, invasion and survival in breast cancer cells
Abstract
Distant metastasis is frequently observed in patients with breast cancer and is a major cause of cancer-related deaths in these patients. Currently, very little is known about the mechanisms that underlie the development of the metastatic phenotype in breast cancer cells. We previously found that metastatic breast cancer cells express high levels of tissue transglutaminase (TG2), but established no direct link between TG2 and metastasis. In this study, we hypothesized that TG2 plays a role in conferring the metastatic phenotype to breast cancer cells. The results obtained suggested that increased expression of TG2 in breast cancer cells contributes to their increased survival, invasion and motility. We further found that TG2 protein in a metastatic breast cancer MDA-MB231 cells was present on the cell surface in close association with integrins beta1, beta4 and beta5. Downregulation of endogenous TG2 by small interfering RNA inhibited fibronectin (Fn)-mediated cell attachment, survival and invasion. Conversely, ectopic expression of TG2 augmented invasion of breast cancer cells and attachment to Fn-coated surfaces. We conclude that TG2 expression in breast cancer cells plays an important role in the development of the metastatic phenotype.
Similar articles
-
Implications of increased tissue transglutaminase (TG2) expression in drug-resistant breast cancer (MCF-7) cells.Oncogene. 2006 May 18;25(21):3049-58. doi: 10.1038/sj.onc.1209324. Oncogene. 2006. PMID: 16449978
-
Up-regulation of fibronectin and tissue transglutaminase promotes cell invasion involving increased association with integrin and MMP expression in A431 cells.Anticancer Res. 2010 Oct;30(10):4177-86. Anticancer Res. 2010. PMID: 21036738
-
Prognostic significance of tissue transglutaminase in drug resistant and metastatic breast cancer.Clin Cancer Res. 2004 Dec 1;10(23):8068-76. doi: 10.1158/1078-0432.CCR-04-1107. Clin Cancer Res. 2004. PMID: 15585642
-
Tissue transglutaminase-mediated chemoresistance in cancer cells.Drug Resist Updat. 2007 Aug-Oct;10(4-5):144-51. doi: 10.1016/j.drup.2007.06.002. Epub 2007 Jul 27. Drug Resist Updat. 2007. PMID: 17662645 Review.
-
Tissue transglutaminase promotes or suppresses tumors depending on cell context.Anticancer Res. 2009 Jun;29(6):1909-19. Anticancer Res. 2009. PMID: 19528447 Review.
Cited by
-
A novel mechanism by which tissue transglutaminase activates signaling events that promote cell survival.J Biol Chem. 2014 Apr 4;289(14):10115-25. doi: 10.1074/jbc.M113.464693. Epub 2014 Feb 25. J Biol Chem. 2014. PMID: 24569994 Free PMC article.
-
Transglutaminase regulation of cell function.Physiol Rev. 2014 Apr;94(2):383-417. doi: 10.1152/physrev.00019.2013. Physiol Rev. 2014. PMID: 24692352 Free PMC article. Review.
-
Transglutaminase 2 and its role in pulmonary fibrosis.Am J Respir Crit Care Med. 2011 Sep 15;184(6):699-707. doi: 10.1164/rccm.201101-0013OC. Epub 2011 Jun 23. Am J Respir Crit Care Med. 2011. PMID: 21700912 Free PMC article.
-
Astrocyte-derived tissue transglutaminase interacts with fibronectin: a role in astrocyte adhesion and migration?PLoS One. 2011;6(9):e25037. doi: 10.1371/journal.pone.0025037. Epub 2011 Sep 16. PLoS One. 2011. PMID: 21949843 Free PMC article.
-
Conformational changes and translocation of tissue-transglutaminase to the plasma membranes: role in cancer cell migration.BMC Cancer. 2014 Apr 11;14:256. doi: 10.1186/1471-2407-14-256. BMC Cancer. 2014. PMID: 24725450 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous